CABA

Cabaletta Bio Inc

1.57

Oct 30 • 7:18 AM ET -0.01 (-0.95%)

Healthcare Biotechnology USA Micro NASD

Peers: KYTX ARTV ALLO FATE IPSC RNAC AUTL NKTX SANA CRBU

| Held by: VTI XBI IWM VXF FESM VTWO IBB IWO IWN DFAS

Index	RUT
Market Cap	266.19M
Enterprise Value	66.80M
Income	-181.32M
Sales	0.00M
Book/sh	1.26
Cash/sh	1.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	156
IPO	Oct 25, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.25
P/C	1.18
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.79
Current Ratio	5.79
Debt/Eq	0.12
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.58
EPS next Y	-1.20
EPS next Q	-0.32
EPS this Y	35.13%
EPS next Y	11.96%
EPS next 5Y	22.07%
EPS past 3/5Y	-5.18% -7.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	41.56%
Sales Y/Y TTM	-
EPS Q/Q	53.72%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	8.82% -

Insider Own	11.59%
Insider Trans	0.00%
Inst Own	83.30%
Inst Trans	64.82%
ROA	-75.36%
ROE	-93.20%
ROIC	-83.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.16%
SMA50	-31.86%
SMA200	-45.03%
Trades

Shs Outstand	167.73M
Shs Float	149.89M
Short Float	26.21%
Short Ratio	7.65
Short Interest	39.29M
52W High	4.23 -62.88%
52W Low	1.32 18.94%
Volatility	8.77% 8.76%
ATR (14)	0.14
RSI (14)	39.07
Beta	3.53
Rel Volume	0.01
Avg Volume	5.14M
Volume	1,803

Perf Week	6.80%
Perf Month	-16.93%
Perf Quarter	-41.64%
Perf Half Y	-46.60%
Perf YTD	-28.31%
Perf Year	-36.44%
Perf 3Y	-88.59%
Perf 5Y	-88.51%
Perf 10Y	-
Recom	1.40
Target Price	13.25
Prev Close	1.59
Price	1.57
Change %	-0.95%

Consensus

Strong Buy

Avg. Price Target

$13.25

Implied Upside

+743.9%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 10, 2025	Resumed	JJefferies	Buy	$14	+791.7%
Dec 20, 2024	Downgrade	EEvercore ISI	Outperform → In-line	$15 → $6	+282.2%
Dec 19, 2024	Downgrade	WWells Fargo	Overweight → Equal Weight	$12 → $6	+282.2%
Oct 10, 2024	Initiated	UUBS	Buy	$10	+536.9%
Feb 05, 2024	Initiated	JJefferies	Buy	$36	+2,193.0%
Nov 29, 2023	Initiated	WWilliam Blair	Outperform	$38	+2,320.4%
Oct 24, 2023	Initiated	CCantor Fitzgerald	Overweight	$40	+2,447.8%
Oct 19, 2023	Initiated	SStifel	Buy	$31	+1,874.5%
Sep 05, 2023	Initiated	CCitigroup	Buy	$22	+1,301.3%
Jul 18, 2023	Initiated	GGuggenheim	Buy	$34	+2,065.6%
Jan 27, 2023	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$3 → $16	+919.1%
Aug 30, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$15 → $3	+91.1%
Dec 08, 2021	Initiated	WWells Fargo	Overweight	$17	+982.8%
Oct 19, 2021	Resumed	MMorgan Stanley	Overweight	$20	+1,173.9%
Jun 30, 2021	Initiated	MMizuho	Buy	$22	+1,301.3%
Jan 08, 2021	Initiated	CChardan Capital Markets	Buy	$21	+1,237.6%
Oct 13, 2020	Initiated	HH.C. Wainwright	Buy	$20	+1,173.9%
Nov 19, 2019	Initiated	MMorgan Stanley	Overweight	$19	+1,110.2%
Nov 19, 2019	Initiated	EEvercore ISI	Outperform	$25	+1,492.4%
Nov 19, 2019	Initiated	CCowen	Outperform

Oct-05-26 04:01PM	Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive) +8.18%
Sep-01-26 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.11%
Aug-13-26 07:30AM	Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge) -5.59%
07:00AM	Loading…
Jun-03-26 07:00AM	Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress (GlobeNewswire)
May-14-26 07:05AM	Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting (GlobeNewswire)
May-04-26 06:35AM	Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering (GlobeNewswire) +30.27%
Apr-28-26 08:00AM	Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel (Business Wire)
08:00AM	Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel (GlobeNewswire)
Apr-27-26 05:00PM	Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting (GlobeNewswire)
Apr-14-26 04:30PM	First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform (Business Wire)
Mar-27-26 01:11PM	This Biotech Stock Could Deliver 350% Returns in 12 Months (GuruFocus.com)
Mar-23-26 07:30AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
05:46AM	Loading…
Mar-07-26 05:46AM	Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference (MarketBeat)
Mar-06-26 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-03-26 09:40AM	Are Medical Stocks Lagging Biodesix (BDSX) This Year? (Zacks)
Feb-24-26 08:00AM	Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +13.45%
Feb-18-26 08:34AM	Here's Why Jacob Funds Established a Position in Cabaletta Bio (CABA) (Insider Monkey) +5.74%
Feb-13-26 12:07AM	Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA (MarketBeat)
Feb-12-26 09:40AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? (Zacks) +10.89%
Feb-05-26 08:00AM	Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.17%
Jan-30-26 12:00PM	What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? (Zacks) -6.55%
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-12-26 08:00AM	Cabaletta Bio Announces 2026 Strategic Priorities (GlobeNewswire) +5.24%
07:30AM	IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms (Business Wire)
Nov-10-25 07:30AM	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks) -10.30%
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December (GlobeNewswire)
05:42AM	Loading…
Oct-31-25 05:42AM	Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials (Insider Monkey) +46.15%
Oct-27-25 07:00AM	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 (GlobeNewswire) +12.96%
Oct-14-25 08:00AM	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant (GlobeNewswire) +16.06%
Oct-09-25 12:00PM	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress (GlobeNewswire) +18.26%
Aug-27-25 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-11-25 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's Why (Zacks)
Aug-07-25 07:30AM	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 09:54AM	Cabaletta Bio Announces Pricing of Public Offering of Securities (GlobeNewswire) -25.53%
06:15AM	Cabaletta Bio Announces Proposed Public Offering of Securities (GlobeNewswire)
06:00AM	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress (GlobeNewswire)
May-29-25 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-15-25 07:00AM	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts (GlobeNewswire) +39.23%
Apr-01-25 12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks) -15.52%
Mar-31-25 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.65%
Mar-19-25 07:00AM	Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform (Business Wire) +6.59%
Feb-26-25 08:00AM	Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 10:21AM	UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire) -14.02%
07:00AM	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire)
Feb-11-25 08:00AM	Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February (GlobeNewswire)
Jan-29-25 08:00AM	Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 (GlobeNewswire)
Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chang David J.	Chief Medical Officer	Jan 21 '26	Buy	2.26	8,800	19,888	8,800	Jan 21 06:56 PM
Binder Gwendolyn	President, Science & Tech.	Jan 21 '26	Buy	2.19	11,312	24,763	31,312	Jan 21 06:56 PM
Tomasello Shawn	Director	Jan 21 '26	Buy	2.21	22,725	50,322	22,725	Jan 21 06:55 PM
Gavel Steve	Chief Commercial Officer	Jan 21 '26	Buy	2.27	22,170	50,215	22,170	Jan 21 06:55 PM
Bollard Catherine	Director	Jan 21 '26	Buy	2.27	4,405	9,982	5,405	Jan 21 06:54 PM
Nichtberger Steven	President & CEO	Jan 21 '26	Buy	2.24	45,000	100,778	1,031,483	Jan 21 06:54 PM
Simon Mark	Director	Jan 21 '26	Buy	2.28	11,061	25,261	147,205	Jan 21 06:53 PM
Gerard Michael	General Counsel	Jan 21 '26	Buy	2.27	6,600	14,979	6,600	Jan 21 06:53 PM

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Co-FounderDr. Steven A. Nichtberger M.D.

M.D.Dr. David J. Chang FACR

President of Science & TechnologyDr. Gwendolyn K. Binder Ph.D.

Ph.D.Dr. Michael C. Milone M.D.

Ph.D.Dr. Aimee Payne M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CABA

Cabaletta Bio Inc

Upgrade your Finviz experience